Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-07
1999-10-19
Kunz, Gary L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 49, 514269, A61K 3170, C07H 19067, C07D23900
Patent
active
059689145
ABSTRACT:
The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.
REFERENCES:
patent: 4017606 (1977-04-01), Hanze et al.
patent: 4757139 (1988-07-01), Kawaguchi et al.
patent: 4874602 (1989-10-01), Calabresi et al.
patent: 4950466 (1990-08-01), Calabresi et al.
patent: 5077280 (1991-12-01), Sommadossi et al.
D.S. Martin et al, Cancer Res., 42, 3964-3970, 1982, "High-Dose 5-Fluorouracil with Delayed Uridine `Rescue` in Mice."
D.S. Martin et al., Cancer Res., 43, 4653, 1983, "Improved Therapeutic Index with Sequential N-Phosphonacetyl-L-asparate plus High-Dose Methotrexate plus High-Dose 5-Fluorouracil and Appropriate Rescue."
Proceedings of AACR, 28, 195, Mar. 1987 -No. 775 -"Phase I Clinical and Pharmacokinetics Study of Orally Administered Uridine."
C.J. van Groeningen et al., Cancer Treatment Reports, vol. 70, No. 6, 745, Jun. 1986, "Clinical and Pharmacokinetic Studies of Prolonged Administration of High-Dose Uridine Intended for Rescue from 5-FU Toxicity."
N.I. Belyanchikova et al, Byulleten `Eksperimental` noi Biologii i Meditsiny, vol. 91, No. 1, 1981, pp. 67-69, "Particular Features of Hematopoiesis in Mice Protected by Deoxycytidine Against the Lethal Effect of Cytosar."
K. Bhalla et al, Blood, vol. 70, No. 2, Aug. 1987, pp. 568-571, "Deoxycytidine Preferentially Protects Normal Versus Leukemic Myeloid Progenitor Cells from Cytosine Arabinoside-Mediated Cytotoxicity."
S. Grant et al, Leukemia Research, M.S. 045, 1986, Pergamon Journals Ltd., "Interaction of Deoxycytidine and Deoxycytidine Analogs in Normal and Leukemic Human Myeloid Progenitor Cells."
K. Bhalla et al, Leukemia, vol. 2 (10) 709-10, 1988, "Phase I Clinical and Pharmacologic Study of Deoxycytidine."
J. Sommadossi et al, Timicrobial Agents and Chemotherapy, vol. 32, No. 7, pp. 997-1001, Jul. 1988, "Uridine Reverses the Tosicity of 3'-Azido-3'-Deoxythymidine in Normal Human Granulocyte-Macrophage Progenitor Cells In Vitro without Impairment of jAntiretroviral Activity."
A. Falcone et al, Blood, vol. 76, No. 11, pp. 2216-2221, (Dec. 1, 1990), "Differential Effecto f Benzylacyclouridine on the Toxic and Therapeutic Effects of Azidothymidine in Mice."
K. Bhalla et al, Blood, vol. 74, No. 6, pp. 1923-1928 (Nov. 1, 1989), "2'-Deoxycytidine Protects Normal Human Bone Marrow Progenitor Cells In Vitro Against the Cytotoxicity of 3'-Azido-3'-Deoxythymidine with Preservation of Antiretroviral Activity."
Z. M. Gomez et al, Antimicrobial Agents and Chemotherapy, vol. 34, No. 7, pp. 1371-1375, Jul. 1990, "Antimalarial Activity of a Combination of 5-Fluoroorotate and Uridine in Mice."
Oligonucleotide Products, Sigma Catalog, pp. 1736-1738.
M. ligo et al, Biochemical Pharmacology, vol. 39, No. 7, 1247 (1990), "Differential Effects of 2,2'-Anhydro-5-Ethyluridine, A Uridine Phosphorylase Inhibitor, on the Antitumor Activity of 5-Fluorouridine and 5-Fluoro-2'-Deoxyuridine."
P. Calabresi et al, Blood, vol. 76, No. 11, pp. 2210-2215 (Dec. 1990), "Benzylacyclouridine Reverses Azidothymidine-Induce Marrow Suppression Without Impairment of Anti-Human Immunodeficiency Virus Activity."
W.D. Ensminger et al, Biochemical Pharmacology, vol. 28, pp. 1541-1545 (1979), "Thymidine 5'-O-Pivaloate, A Prodrug Derivative of Thymidine with Potential Applications in High-Dose Methotrexate Therapy."
Martin et al, Journal of Pharmaceutical Sciences, vol. 76, No. 2, pp. 180-183, issued Feb. 1987, "Synthesis and Antiviral Activity of Various Esters of 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine."
Casida et al, Biochemical Pharmacology, vol. 15, pp. 627-644, Issued 1966, "3',5'-Diesters of 5-Fluoro-2'-Deoxyuridine and Thymidine Hydrolysis by Esterases in Human, Mouse, and Insect Tissue."
Losse et al, Chemical Abstracts, vol. 118, Issued 1993, "A convenient pathway to 2'-(tert-butyloxycarbonyl)-ribonucleosides," p. 884, col. 1, abstr. No. 60026c, J. Prakt. Chem./Chem.-Ztg., 334(6), 531-532.
Bamat Michael K.
von Borstel Reid
Kunz Gary L.
Pro-Neuron, Inc.
LandOfFree
Treatment of chemotherapeutic agent and antiviral agent toxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of chemotherapeutic agent and antiviral agent toxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of chemotherapeutic agent and antiviral agent toxicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2055476